Sunday, July 12, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 39 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 10280171

    Heterocyclic inhibitors of PTPN11

    The Board of Regents of the University of Texas System · Granted May 7, 2019 · Expires May 2, 2039

    granted

  2. US 10280422

    MiR-92 inhibitors and uses thereof

    MIRAGEN THERAPEUTICS, INC. · Granted May 7, 2019 · Expires May 2, 2039

    granted

  3. US 10273218

    BCL-3 inhibitors

    University College Cardiff Consultants Limited · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  4. US 10273233

    Inhibitors of influenza viruses replication

    Vertex Pharmaceuticals Incorporated · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  5. US 10272074

    Inhibitors of glucocorticoid receptor translocation

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  6. US 10272132

    Peptide and peptidomimetic inhibitors

    RA PHARMACEUTICALS, INC. · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  7. US 10272084

    Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy

    The Board of Regents of the University of Texas System · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  8. US 10266549

    ULK1 inhibitors and methods using same

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  9. US 10265313

    Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  10. US 10266488

    4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase

    THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  11. US 10266539

    Polymorph of Syk inhibitors

    GILEAD CONNECTICUT, INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  12. US 10266542

    EZH2 inhibitors

    Mirati Therapeutics, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  13. US 10258627

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Apr 16, 2019 · Expires Apr 11, 2039

    granted

  14. US 10253039

    Inhibitors of bacterial DNA gyrase with efficacy against gram-negative bacteria

    The Regents of the University of California · Granted Apr 9, 2019 · Expires Apr 4, 2039

    granted

  15. US 10253044

    9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 9, 2019 · Expires Apr 4, 2039

    granted

  16. US 10246463

    Hypoxia-inducible factor 1 (HIF-1) inhibitors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted

  17. US 10239837

    Piperidine derivatives as HDAC1/2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  18. US 10239832

    N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  19. US 10233170

    2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use

    Rigel Pharmaceuticals, Inc. · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  20. US 10233209

    Inhibitors of the farnesoid x receptor and uses in medicine

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  21. US 10233152

    LSD1 inhibitors

    Mirati Therapeutics, Inc. · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  22. US 10231974

    Pharmaceutical composition effective in preventing the adverse effects associated with the prolonged use of dihydrofolate reductase inhibitors

    Compass Therapeutics LLC · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  23. US 10226452

    Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments

    The Regents of the University of California · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted

  24. US 10226468

    Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

    Asana BioSciences, LLC · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.